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OBJECTIVE—To explore whether treatment with pioglitazone was associated with risk of
incident cancer at the 10 most common sites (prostate, female breast, lung/bronchus, endome-
trial, colon, non-Hodgkin lymphoma [NHL], pancreas, kidney/renal pelvis, rectal, and mela-
noma).
RESEARCH DESIGN AND METHODS—A cohort study of 252,467 patients aged $40
years from the Kaiser Permanente Northern California Diabetes Registry was conducted. All pre-
scriptions for diabetes medications were identiﬁedby pharmacy records.Cox proportional hazards
modelswereusedtoexaminetheassociationbetweenriskofincidentcancerandeveruse,duration,
dose, and time since initiation of pioglitazone (modeled as time-dependent variables).
RESULTS—In models adjusted for age, sex, year of cohort entry, race/ethnicity, income,
smoking, glycemic control, diabetes duration, creatinine levels, congestive heart failure, and
use of other diabetes medications, the hazard ratio (HR) for each cancer associated with ever
useofpioglitazonerangedfrom0.7to1.3,withall95%CIsincluding1.0.Therewasasuggestion
of an increased risk of melanoma (HR 1.3 [95% CI 0.9–2.0]) and NHL (1.3 [1.0–1.8]) and a de-
creased risk of kidney/renal pelvis cancers (0.7 [0.4–1.1]) associated with ever use of pioglitazone.
These associations were unaltered with increasing dose, duration, or time since ﬁrst use.
CONCLUSIONS—Wefound noclearevidenceof anassociationbetweenuseof pioglitazone
and risk of the incident cancers examined. Because the maximum duration of follow-up was
fewer than 6 years after the initiation of pioglitazone, longer-term studies are needed.
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T
he thiazolidinediones (TZDs) bind
to the g subtype of peroxisome
proliferator–activated receptors
(PPARs).Pioglitazone(ACTOS)isaPPARg
ligand used in the treatment of type 2 di-
abetes. It is indicated as an adjunct to diet
and exercise to improve glycemic control.
It is generally not used as a ﬁrst-line ther-
apy (1).
PPARg agonists have been shown to
induce apoptosis in several malignant cell
lines (2,3) and to inhibit the invasive activ-
ity of colon and breast cancers cells (4–7).
In contrast, animal toxicity studies have
suggested a possible increased cancer
risk in multiple organs in association
w i t haw i d ev a r i e t yo fP P A R g and dual
PPARa/g agonists (8). Recent ﬁndings
s u g g e s tt h a ts y n t h e t i cP P A R g ligands
may affect cell growth independent of
the presence of PPARg (9,10). Clinical
trial and epidemiologic data on TZDs
and cancer risk are limited and results
from the few studies conducted to date
have been conﬂicting (11–17).
Because of the concern of a possible
association between pioglitazone and
bladder cancer risk (15–17), the Euro-
pean Medicines Agency requested that
Takeda,themanufacturerofpioglitazone,
undertake an epidemiologic study of pio-
glitazone useand therisk of cancer at sev-
eral sites. The authors of this article
developed the study protocol, which
was approved bytheEuropeanMedicines
Agency. Because we were already con-
ducting a study of pioglitazone use and
bladder cancer risk, the aim of this study
was to explore whether pioglitazone
treatment is associated with the risk
ofincidentcanceratthe10sites,exclud-
ing the bladder, with the highest inci-
dence in the U.S.: prostate, female
breast, lung/bronchus, endometrial, co-
lon, non-Hodgkin lymphoma (NHL),
pancreas, kidney/renal pelvis, rectal,
and melanoma.
RESEARCH DESIGN AND
METHODS—T h es o u r c ep o p u l a t i o n
was identiﬁed from the Kaiser Perma-
nente Northern California (KPNC) Di-
abetes Registry (18,19), which identiﬁes
patients from four data sources: primary
hospital discharge diagnoses of diabetes,
two or more outpatient visit diagnoses of
diabetes, any prescription for a diabetes-
related medication, or any record of an
abnormal HbA1c test (.6.7%).
Men and women with diabetes were
eligible for the cohort if they met any of
the following criteria: 1)w e r ei nt h e
KPNC Diabetes Registry, aged $40 years
and members of KPNC as of 1 January
1997; 2) were in the diabetes registry,
reached age 40 years between 1 January
1997 and 30 June 2005, and were KPNC
m e m b e r so nt h e i r4 0 t hb i r t h d a y ;o r3)
joined KPNC after 1 January 1997 and
were aged $40 years when they were
identiﬁed by the diabetes registry be-
tween 1 January 1997 and 30 June 2005.
Individuals were excluded from the
cohort if they 1) were ,40 years of age
between 1 January 1997 and 30 June
2005; 2) had no KPNC medication bene-
ﬁts at the time of cohort entry (baseline);
3)hadagapinbeneﬁtsorKPNCmember-
ship for $4 months that started in the 4
months following cohort entry; or 4)h a d
evidence in the registry of a cancer diag-
nosis prior to cohort entry.
Each patient’s baseline was deﬁned as
the date of cohort entry (i.e., the ﬁrst date
that inclusion criteria were met). For all
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ORIGINAL ARTICLEoutcomesexceptpancreaticcancer,follow-
up started 6 months after cohort entry to
allow sufﬁcient time for patients to ﬁll
at least two prescriptions of diabetes med-
ication. For pancreatic cancer, follow-up
began12monthsaftercohortentrytomin-
imize an association between the initiation
of diabetes medication and incident cancer
that was due to prodromic hyperglycemia
thatoftenprecedesthediagnosisofpancre-
atic cancer (20).
Follow-up ended at the ﬁrst occur-
rence of one of the following events: 1)a
gap of $4 months in either membership
or prescription beneﬁts, 2) a diagnosis of
site speciﬁcc a n c e r ,3)d e a t hf r o ma n y
cause, or 4) end of the study (31 Decem-
ber 2005).
We identiﬁed all prevalent and in-
cident invasive cancers (for all sites) by
linkage with the KPNC Cancer Registry.
The KPNC Cancer Registry is a contrib-
utor to the Surveillance, Epidemiology,
and End Results (SEER) program. All
invasive cancers are staged according to
SEER guidelines as local, regional, dis-
tant, or undetermined.
Forallcohortmembers,weidentiﬁed
all prescriptions for diabetes medications
from the pharmacy clinical database. Di-
abetes medications were categorized as
pioglitazone, other TZDs (almost exclu-
sively troglitazone), metformin, insulin,
sulfonylureas, and other oral agents (e.g.,
miglitol,acarbose,nataglinide,repaglinide).
Cohortmemberswerecategorizedas“ever
users”ofpioglitazonewhentheyhadﬁlled
two prescriptions for pioglitazone in a
6-month period. Exposure to other dia-
betes medications was similarly classi-
ﬁed. Separate variables were created to
indicate never having received any pre-
scriptions for diabetes medication and
never having ﬁlled at least two prescrip-
tions for the same medication within
6m o n t h s .
Time since the initiation of pioglita-
zone was calculated by counting the in-
terval,indays,sincethedateofthesecond
pioglitazone prescription. Cumulative
duration of pioglitazone use was mea-
sured by counting the days supply for
each prescription, starting with the ﬁrst
prescription. If the subsequent prescrip-
tion was ﬁlled within 30 days of the
expected end date for the previous pre-
scription, we assumed that therapy was
uninterrupted. If there were no reﬁlls
within 30 days of the expected end date
of the previous prescription, we assumed
a gap in therapy starting 30 days after the
datethatthepreviousprescriptionshould
Table 1—Characteristics of 252,467 patients with diabetes by pioglitazone use: KPNC
Diabetes Registry, 1997–2005
Ever user of pioglitazone† Never user of pioglitazone§
n 26,364 226,103
Total person-years in each age-group*
40–49 7,733 (11.6%) 134,484 (14.4%)
50–59 19,588 (29.3%) 242,792 (26.0%)
60–69 21,029 (31.4%) 253,584 (27.2%)
$70 18,533 (27.7%) 302,526 (32.4%)
Female 12,438 (47.2%) 105,165 (46.5%)
Income
Low‡ 14,100 (53.5%) 121,581 (53.8%)
High 11,821 (44.8%) 99,038 (43.8%)
Missing 443 (1.7%) 5,484 (2.4%)
Race/ethnicity
Non-Hispanic white 12,628 (47.9%) 106,267 (47.0%))
African American 2,286 (8.7%) 21,086 (9.3%)
Asian or Paciﬁc Islander 2,895 (11.0%) 26,018 (11.5%)
Hispanic 2,717 (10.3%) 19,304 (8.5%)
Other 1,479 (5.6%) 11,660 (5.1%)
Missing 4,359 (16.5%) 41,768 (18.5%)
Current smoking
Yes 5,105 (19.4%) 41,197 (18.2%)
No 21,259 (80.6%) 178,245 (78.8%)
Missing 0 (0.0%) 6,661 (2.9%)
Renal function
Normal creatinine 19,750 (74.9%) 178,677 (79.0%)
Elevated creatinine** 1,262 (4.8%) 19,109 (8.5%)
Missing 5,352 (20.3%) 28,317 (12.5%)
Congestive heart failure 970 (3.7%) 14,542 (6.4%)
Baseline HbA1c (%)
,7.0% 4,184 (15.9%) 72,576 (32.1%)
7.0–7.9% 4,384 (16.6%) 39,661 (17.5%)
8.0–8.9% 3,273 (12.4%) 20,597 (9.1%)
9.0–9.9% 2,568 (9.7%) 14,068 (6.2%)
$10.0% 5,928 (22.5%) 34,108 (15.1%)
Missing 6,027 (22.9%) 45,093 (19.9%)
Time since diabetes diagnosis (years)
0–4 13,793 (52.3%) 154,915 (68.5%)
5–9 2,684 (10.2%) 10,980 (4.9%)
$10 2,796 (10.6%) 19,311 (8.5%)
Missing 7,091 (26.9%) 40,897 (18.1%)
Other TZDs† 2,772 (10.5%) 2,803 (1.2%)
Metformin† 20,418 (77.5%) 89,384 (39.5%)
Sulfonylureas† 21,550 (81.7%) 111,725 (49.4%)
Other oral agents† 1,217 (4.6%) 2,003 (0.9%)
Insulin† 9,880 (37.5%) 41,631 (18.4%)
Estrogen† only*** 2,478 (19.9%) 14,492 (13.8%)
Estrogen† plus progestin† *** 1,682 (13.5%) 7,729 (7.4%)
Pioglitazone use during follow-up
Time since starting pioglitazone (months)
Median (range) 28.8 months (2.4–74.4) N/A
,12 months 6,698 (25.4%) N/A
12–23 months 4,938 (18.7%) N/A
24–35 months 4,391 (16.7%) N/A
36–47 months 3,992 (15.1%) N/A
48+ months 6,345 (24.1%) N/A
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Pioglitazone and cancer incidencehave ended. To calculate cumulative dose
of pioglitazone, we used any prescrip-
tionthatwasdispensedpriortoanevent
date (including the ﬁrst prescription)
and the total prescribed dose (i.e., num-
berofpillsintheprescriptionmultiplied
by the dose of the pills) was assumed to
have been consumed. However, when a
prescriptions’dayssupplyextendedbeyond
the date of an event, the total consumed
dose was reduced to reﬂect the cumulative
dose consumed by the event date.
Information on the confounders
shown in Table 1 was obtained from elec-
tronic medical records. For smoking, the
electronic medical record data were sup-
plementedwithdatafromapostalsurvey.
With the exception of smoking, all con-
founders were measured using data re-
corded at or before baseline. In addition,
approximately 19% of the cohort had
been invited to participate in a postal sur-
vey conducted in 1994–1996, which ob-
tained information on the following
potential confounders: duration of diabe-
tes, smoking, race/ethnicity, and BMI.
Cox proportional hazards regression
models were used to provide point and
interval estimates of the relative hazard
of the 10 cancers associated with ever use
of pioglitazone, time since ﬁrst use, cu-
mulative duration, and cumulative dose.
In all regressions, these measures of
pioglitazone exposure, along with mea-
sures of other diabetes medications and
indicator variables for “never use of any
diabetes medication” and “never ﬁlled
two prescriptions of the same medica-
tion within 6 months,” were treated as
time-dependent covariates with time since
cohort entry as the time scale. Speciﬁcally,
allfollow-uptimefromentryuntilthedate
that the patient ﬁrst met the deﬁnition of
ever use was attributed to the never use
group, and once a patient met the deﬁni-
tion of ever use, the patient was consid-
ered exposed from that point forward,
even if he/she discontinued the medica-
tion. The reference group for calculation
of the hazard ratios (HRs) associated with
ever use of pioglitazone (with or without
other diabetes medications) was never
use of pioglitazone at that point of time,
whichbydeﬁnitionincludedthosetreated
withanydiabetesmedicationsotherthan
pioglitazone and those with only dietary
therapy.
Analyses of each cancer site were con-
ducted with control for two sets of cova-
riates. Model 1 included the pioglitazone
exposuremeasure,ageatcohortentry,use
of other diabetes medications, and calen-
dar year of entry into the cohort. Model 2
included all the Model 1 covariates along
with sex, race/ethnicity, baseline HbA1c,
diabetes duration, renal function, and his-
tory of congestive heart failure. Results in
Model 1 and Model 2 were very similar,
a n da ss u c hw er e p o r to n l yt h er e s u l t s
from the fully adjusted models (Models
2). Among women, we ran additional
models adjusting for hormone therapy,
which was treated as time-varying. All
covariates were categorized as shown in
Table 1 and included a missing category.
ThestudywasapprovedbytheKaiser
Permanente and University of Pennsylva-
nia Institutional Review Boards.
RESULTS—The characteristics of the
studypopulation,bypioglitazoneuse,are
shown in Table 1. By the end of follow-
up, 26,364 patients had been exposed to
pioglitazone. The mean follow-up time
for patients who ever used pioglitazone
and patients who never used pioglitazone
w a s2 . 5 4y e a r s( r a n g e0 . 1 –6.2) and 3.7
years (0.01–8.5), respectively. There
were 9,082 cohort members diagnosed
with an incident cancer at 1 or more of
the 10 sites of interest, ranging from 373
patients diagnosed with melanoma to
2,105 with prostate cancer. Table 2 pro-
vides adjusted HR estimates for the asso-
ciation between ever use of pioglitazone
and site-speciﬁc cancer risk. The HRs as-
sociated with ever use of pioglitazone
ranged from 0.7 to 1.3, with all 95% CIs
including 1.0. There was a suggestion of
an increased risk of melanoma and NHL
associated with ever use of pioglitazone
(HR 1.3 [95% CI 0.9–2.0] and 1.3 [1.0–
1.8], respectively), and a decreased risk
of cancers of the kidney and renal pelvis
(0.7 [0.4–1.1]). For melanoma, we ob-
served a similar increase with the use of
sulfonylureas (1.3 [0.9–1.8]). For NHL,
we observed an increase with the use of
other hypoglycemic medications, which
included miglitol, acarbose, nataglinide,
and repaglinide (1.7 [1.0–3.1]).
Everuseofsulfonylureasandeveruse
of insulin were associated with an in-
creased risk of pancreatic cancer (HR 2.3
[95% CI 1.7–3.2] and 3.1 [2.4–4.0], re-
spectively), whereas ever use of insulin
was associated with a decreased risk of
prostate cancer (0.8 [0.7–0.9]). Metfor-
min was not associated with either a de-
crease or an increase in the risk of the
cancers studied; only a small increased
risk in pancreatic cancer was observed
inassociation with ever use of metformin.
In general, we saw little evidence of
linear trends for time since initiation,
duration or dose of pioglitazone use,
and risk of cancer at any site (Table 3).
For cancer of the corpus uteri, we did
see a statistically signiﬁcant trend (P =
0.049) of increasing risk with increasing
time since initiation of pioglitazone. For
NHL, there was a statistically signiﬁcant
trend (P = 0.048) for dose (although the
HRforthehighestdosewaslowerthanfor
the intermediate dose). For NHL, the
HRs for pioglitazone use initiated 1–2
years prior, 1–2 years of cumulative pio-
glitazone use, and cumulative dose of
pioglitazone of 9,001–25,000 mg were
1.8 (95% CI 1.1–2.9), 1.6 (1.0–2.7), and
1.8 (1.2–2.8), respectively. HRs for longer
Table 1—Continued
Ever user of pioglitazone† Never user of pioglitazone§
Duration of therapy (months)
Median (range) 19.2 months (2.4–74.4) N/A
,12 months 8,898 (33.8%) N/A
12–23 months 6,782 (25.7%) N/A
24–35 months 4,439 (16.8%) N/A
36+ months 6,245 (23.7%) N/A
Cumulative dose (mg)
Median (range) 15,000 mg (450–90,000) N/A
1–9,000 mg 9,167 (34.8%) N/A
9,001–25,000 mg 8,899 (33.7%) N/A
.25,000 mg 8,298 (31.5%) N/A
Data are n (%) unless otherwise indicated. N/A, not applicable. †Filled at least two prescriptions within a
6-month period. *With pioglitazone use treated as a time-varying variable. **Creatinine $1.4 for women
and $1.5 for men. ‡Low income deﬁned as median household income in census block below the cohort
average($59,000).***Datafrom12,438womentreatedwithpioglitazoneand105,165womennevertreated
with pioglitazone. §All comparisons between ever user of pioglitazone and never user of pioglitazone have
P values ,0.05 except use of estrogen only (P = 0.06).
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Ferrara and Associateslengths of time since initiation, longer
durations of use, and higher dose of
pioglitazone were lower, but the number
of exposed cases was also small. Com-
pared with never users of pioglitazone,
the risk of melanoma was approximately
twofold higher among those who initiated
pioglitazone therapy 1–2 years prior and
amongthosewhosedurationofpioglitazone
therapy was 1–2y e a r s .H R sf o rl o n g e r
times since initiation and duration were
lower, although the numbers of exposed
cases were small.
In order to assess whether our results
were biased by incorrectly measuring
time since ﬁrst use, duration, and dose
of pioglitazone use among patients who
joined KPNC after pioglitazone was ﬁrst
available, analyses were repeated among
180,203 patients who had been KPNC
members before 1 January 1997. There-
fore, in this analysis only new users of
pioglitazone were included in the ex-
posed group. Similar results were ob-
served in this subgroup and in the full
cohort in relation to the association of
time since ﬁrst use, duration, and dose of
pioglitazone with risk of cancer at each
site (data not shown).
We further examine the associations
between pioglitazone use and risk of
melanoma, NHL, and kidney/renal pelvis
cancers by assessing the stage of cancer at
diagnosis. Speciﬁcally, the distribution of
local, regional, distant, or undetermined
stages at the diagnosis in patients who
ever used pioglitazone and in patients
who never used pioglitazone for mela-
noma was 86, 6, 8, and 0 vs. 85, 6, 5, and
3%, respectively (P =0 . 6 7 ) ;f o rN H Lt h e
distribution was 28, 16, 54, and 2 vs. 33,
16, 48, and 3%, respectively (P = 0.88);
and for kidney/renal pelvis cancers the
distribution was 55, 18, 18, and 9 vs.
58, 19, 21, and 2%, respectively (P =
0.29).
Results were similar among the
117,603 women, both before and after
adding use of hormone therapy to the
fully adjusted model (data not shown).
Among the 52,331patients forwhom
survey data were available on height and
weight, diabetes duration, smoking his-
tory, and race/ethnicity, inclusion of BMI
and other survey variables in the models
did not appreciably alter point estimates
for the association between ever use of
pioglitazone and the risk of cancer (data
not shown).
CONCLUSIONS—We found no sug-
gestion of an association between the use
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Pioglitazone and cancer incidenceofpioglitazoneandriskofincidentcancer
at 7 of the 10 sites. There was some
suggestion that use of pioglitazone was
associated with an increased risk of mel-
anoma and NHL and a decreased risk of
the kidney/renal pelvis cancers, but the
sizes of the observed risk increases and
decreases were small (30%) and the con-
ﬁdence intervals all included unity. In
addition,theassociationsdidnotincrease
with extended duration of use, cumulative
dose,ortimesinceﬁrstuseofpioglitazone,
which makes a causal association less
likely.However,ourpowerwassomewhat
limited given the relatively small number
of cases for NHL, kidney/renal pelvis
cancers, and melanoma. Lastly, these pos-
sible associations need to be interpreted
with caution given the large number of
comparisons that were performed in this
study.
Several limitations should be consid-
ered when interpreting our results. Pio-
glitazone was approved foruseinthe U.S.
in 1999, so there were few prescriptions
for this medication in our cohort prior
to 2001. Therefore, we were only able
to examine recently initiated therapy
and short-term use (median 1.6 years) of
pioglitazone, albeit with longer use and
follow-up than in previously published
studies(11–13).However,thelatencype-
riod for many carcinogens is often many
years or even decades. It is also possible
that there is some residual confounding
from some variables we have not mea-
sured, and we also lacked complete infor-
mation on several potentially important
confoundersforthe fullcohort.However,
in analyses restricted to individuals with
information on race/ethnicity, BMI, and
diabetes duration, we found little evi-
dence of confounding by these factors.
Finally, it is important to consider the
possibility that any increased or de-
creased risk of cancer observed in associ-
ation with pioglitazone use could in fact
be due to other diabetes medications re-
ducingorincreasingthecancerrisk.Some
research has suggested that metformin use
isassociatedwithareducedriskforvarious
cancers (21), and others have suggested
that insulin use might be associated with
increased cancer risk (22). However, we
did not observe any signiﬁcant association
between ever use of metformin or insulin
and the risk of melanoma, NHL, and
kidney/renal pelvis cancer.
There are several major strengths
to be noted. First, enrollees of KPNC re-
ceive virtually all of their health care from
this prepaid, integrated health plan. The
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Ferrara and AssociatesKPNC Cancer Registry is also well estab-
lished and as a contributor to SEER, held
to high standards of quality. This study is
alsostrengthenedbytheavailabilityofthe
KPNC pharmacy database. By requiring
two prescriptions within a 6-month pe-
riod,wehaveminimizedmisclassiﬁcation
of unexposed patients as exposed.
Previous observational studies
(11–13,23)ofTZDuseamongdiabeticpa-
tients and cancer risk addressed only a
small number of cancers and had several
important limitations, including only very
short-term exposure to pioglitazone, no
analysesfordoseordurationofpioglitazone
use, and missing data on important con-
founderssuch asrace/ethnicity and smok-
ing. Previous studies have not identiﬁed
signals of increased cancer incidence. In
our study, we observed possible weak sig-
nals for NHL and melanoma, two cancers
that were not examined in the prior stud-
ies. We did not conﬁrm the decreased
risk of lung cancer and colon or rectal
cancer,aswassuggestedbyGovindarajan
et al. (12).
We found no clear evidence of an
association between use of pioglitazone
and risk of the incident cancer at the sites
examined. This study of relatively short-
term use could miss effects that require
longer-term exposure or follow-up to
become evident. Although the study
was conducted in a large cohort of di-
abetic patients, we had relatively few
pioglitazone-exposed cancer cases at
most sites, limiting our precision, es-
pecially for risk estimates associated
with duration, dose, and latency. Stud-
ies with longer follow-up are needed
before any ﬁrm conclusions can be
reached regarding pioglitazone and can-
cer risk. A longer follow-up study in this
cohort is ongoing.
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